Autolus Therapeutics Ltd Total Assets
Autolus Therapeutics Ltd total assets. Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) holds total assets worth $493.23 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Autolus Therapeutics Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Autolus Therapeutics Ltd (2015–2025)
Total assets of Autolus Therapeutics Ltd from 2015 to 2025. This chart illustrates how Autolus Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See AUTL stock price for real-time trading data and today's change.
Autolus Therapeutics Ltd - Asset Composition Analysis
Autolus Therapeutics Ltd Total Assets Breakdown (December 2025)
Autolus Therapeutics Ltd total assets breakdown as of December 2025. Autolus Therapeutics Ltd's total assets of $493.23 Million consist of 74.0% current assets and 26.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.7% |
| Accounts Receivable | $75.79 Million | 12.9% |
| Inventory | $33.21 Million | 5.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.81 Million | 3.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Autolus Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Autolus Therapeutics Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Autolus Therapeutics Ltd's current assets represent 74.0% of total assets in 2025, an increase from 50.7% in 2015.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, down from 45.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 45.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 12.9% of total assets.
Autolus Therapeutics Ltd Competitors by Total Assets
Key competitors of Autolus Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Autolus Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.89 | 8.43 | 6.84 |
| Quick Ratio | 4.40 | 8.07 | 6.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $267.30 Million | $506.10 Million | $201.81 Million |
Autolus Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Autolus Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.95 |
| Latest Market Cap to Assets Ratio | 0.69 |
| Asset Growth Rate (YoY) | -24.7% |
| Total Assets | $589.07 Million |
| Market Capitalization | $404.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Autolus Therapeutics Ltd's assets below their book value (0.69x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Autolus Therapeutics Ltd's assets decreased by 24.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Autolus Therapeutics Ltd (2015–2025)
The table below shows the annual total assets of Autolus Therapeutics Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $589.07 Million | -24.74% |
| 2024-12-31 | $782.73 Million | +108.51% |
| 2023-12-31 | $375.38 Million | -23.43% |
| 2022-12-31 | $490.27 Million | +20.89% |
| 2021-12-31 | $405.56 Million | +37.83% |
| 2020-12-31 | $294.24 Million | -3.06% |
| 2019-12-31 | $303.53 Million | +39.45% |
| 2018-12-31 | $217.66 Million | 0.00% |
| 2018-09-30 | $217.66 Million | +46.41% |
| 2017-12-31 | $148.66 Million | +334.94% |
| 2016-12-31 | $34.18 Million | +50.87% |
| 2015-12-31 | $22.66 Million | -- |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more